Simon Noble, MBBS, Cardiff University, Cardiff, UK, takes us on the journey of the management of cancer associated thrombosis (CAT) over time. Where once warfarin was the only anticoagulant, low molecular weight heparin emerged to change the game. Prof. Noble then highlights the significance of the release of direct acting oral anticoagulants (DAOACs). This interview took place at the International Society of Oncology Pharmacy Practitioners (ISOPP) Symposium 2019, hosted by the British Oncology Pharmacy Association (BOPA), held in London, UK.